Drug Information

General Information
Drug ID
DR01410
Drug Name
Guanabenz
Synonyms
GBZ; Guanabenzo; Guanabenzum; Wytensin; Guanabenz acetate; Guanabenz monoacetate; Wy 8678; Wy 8678 base; BR-750; Guanabenz [USAN:INN]; Guanabenz(USAN); Guanabenzo [INN-Spanish]; Guanabenzum [INN-Latin]; Wy-8678; Wytensin (TN); Guanabenz (USAN/INN); [(2,6-Dichlorobenzylidene)amino]guanidine; N-((2,6-Dichlorobenzylidene)amino)guanidine; Guanidine, ((2,6-dichlorobenzylidene)amino)-(8CI); N-(2,6-Dichlorobenzylidene)-N'-amidinohydrazine; ((2,6-Dichlorobenzylidene)amino)guanidine; 2,6-Dichlorobenzylideneaminoguanidine;2-((2,6-Dichlorophenyl)methylene)-hydrazinecarboximidamide; 2-[(E)-(2,6-dichlorophenyl)methylideneamino]guanidine
Drug Type
Small molecular drug
Indication Hypertension [ICD11: BA00] Approved [1]
Therapeutic Class
Sympatholytics
Structure
3D MOL 2D MOL
Formula
C8H8Cl2N4
Canonical SMILES
C1=CC(=C(C(=C1)Cl)C=NN=C(N)N)Cl
InChI
InChI=1S/C8H8Cl2N4/c9-6-2-1-3-7(10)5(6)4-13-14-8(11)12/h1-4H,(H4,11,12,14)/b13-4+
InChIKey
WDZVGELJXXEGPV-YIXHJXPBSA-N
CAS Number
CAS 5051-62-7
Pharmaceutical Properties Molecular Weight 231.08 Topological Polar Surface Area 76.8
Heavy Atom Count 14 Rotatable Bond Count 2
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 2
XLogP
1.7
PubChem CID
5702063
PubChem SID
9246 , 113005 , 15390940 , 17434456 , 24607029 , 26665151 , 26751943 , 47206274 , 47795034 , 48018892 , 48169358 , 48243349 , 48318400 , 49698340 , 50064822 , 50070697 , 50104618 , 50104619 , 57364886 , 78424678 , 81642163 , 85209545 , 85787575 , 88878415 , 90341577 , 92098556 , 92308809 , 103164806 , 103826246 , 103936653 , 114069183 , 117464955 , 124749846 , 124886953 , 126876159 , 131342553 , 131342557 , 134337546 , 134984370 , 137010571 , 137144691 , 137149965 , 139524299 , 145257345 , 160963974 , 164037969 , 164819317 , 175266630 , 176483965 , 179038222
ChEBI ID
CHEBI:5553
TTD Drug ID
D0L4HY
DT(s) Transporting This Drug P-GP Transporter Info P-glycoprotein 1 Substrate [2]
References
1 Guanabenz was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.